UTI Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 21-11-2024
₹ 312.31
▲0.2%
1D
Inception Returns
17.1%
/yr
About UTI Healthcare Fund Direct Growth
UTI Healthcare Fund Direct Growth is an equity fund. This fund was started on 1 January, 2013. The fund is managed by . The fund could potentially beat inflation in the long-run.
Key Parameters
- UTI Healthcare Fund Direct Growth has ₹1187 Cr worth of assets under management (AUM) as on Oct 2024 and is less than category average.
- The fund has an expense ratio 1.3.
Returns
UTI Healthcare Fund Direct Growth has given a CAGR return of 17.13% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 44.42%, 21.05% and 28.45% respectively.
Holdings
UTI Healthcare Fund Direct Growth has allocated its funds majorly in Health, Cash Equivalent, Government, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Ajanta Pharma Ltd, Dr Reddy's Laboratories Ltd, Gland Pharma Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of UTI Healthcare Fund Direct Growth
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. UTI Healthcare Fund Direct Growth has no lock in period.
Historical NAV & Returns
Annualised
▲
▼
264 people have invested ₹ 86.5L in UTI Healthcare Fund Direct Growth in the last three months
INDmoney Rank for UTI Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
Beats FD returns for both 3Y & 5Y duration
No bad points found for this fund.
UTI Healthcare Fund Direct Growth Overview
| Expense ratio | 1.28% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹1187 Cr |
| Inception Date | 1 January, 2013 |
| Min Lumpsum/SIP | ₹5000/₹500 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 24.75% |
| STCG | Redeeming before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (21-Nov-24)
Fund Distribution
as on (31-Oct-24)
Small cap
35.6%
Large cap
32.8%
Mid cap
26.6%
Sector Allocation
Health
97.4%
Basic Materials
1.5%
Financial Services
1.1%
All changes are between Aug'24 and Oct'24
- This fund’s returns stands at -1.52% whereas the fund’s underlying benchmark Nifty 500 returns stands at -6.52% as on Oct'24
- This fund outperformed Nifty 500 by 4.99% in Oct'24
- AUM of the fund stands at 1.2K Cr as of Oct'24
- AUM decreased by 14.4 Cr between Oct'24 and Sep'24
Top Stocks bought last month
Gland Pharma Ltd's allocation increased from 2.54% to 3.7%
Sanofi Consumer Healthcare India Ltd's allocation increased from 0.47% to 0.99%
Emcure Pharmaceuticals Ltd's allocation increased from 1.93% to 2.42%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 11.79 % to 11.29 %
Cipla Ltd's allocation decreased from 6.2 % to 5.89 %
Dr Reddy's Laboratories Ltd's allocation decreased from 4.89 % to 4.67 %
Small Cap allocation has gone up from 34.6% to 35.6%
Mid Cap allocation has gone up from 25.2% to 26.6%
Large Cap allocation has gone down from 34.5% to 32.8%
Cash allocation has gone down from 3.3% to 1.4%
Debt allocation has gone up from 0.1% to 0.1%
Top 3 Sectors in October were Health, Government & Basic Materials
Oct'24
Health
97%
Government
7%
Basic Materials
2%
Sep'24
Health
97%
Government
3%
Basic Materials
1%
See all
Top Growth Drivers | 1M Return |
|---|---|
 Suven Pharmaceuticals Ltd | 0.2% |
Loading...
We are taking more time than usual
Fund House
UTI Asset Management Co Ltd
Total Schemes
Total AUM
₹2.37L Cr
as on 31-Oct-2024
Address
PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051
Phone
+912266786666
Website
service@uti.co.in
Mutual Fund Insights
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.28% which is lower than the category average expense ratio of 1.39%.
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 24.27% return, outperforming this fund by 3.22% per annum.
In the last 5 years, DSP Healthcare Fund Direct Growth has given 32.68% return, outperforming this fund by 4.23% per annum.
Over the last 6 months, this fund has experienced a 25.8% growth in AUM moving from 943.34 Cr to 1.18K Cr.
Over the last 1 year, this fund has decreased expense ratio by 7.9% moving from 1.39 to 1.28.
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 51.62% return, outperforming this fund by 7.2%.
UTI Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 17.13% since inception which is less than its category average return of 24.93%
Fund Allocations
This fund has an allocation of 98.47% in Equity, 0.11% in Debt and 1.42% in Cash related instruments
AUM size ₹1187 Cr
This fund has AUM of ₹1187 Cr which is less than its category average of ₹ 2001 Cr
Expense Ratio 1.28%
This fund has an expense ratio of 1.28% which is less than its category average expense ratio of 1.33%
Frequently Asked Questions for UTI Healthcare Fund Direct Growth
The current NAV of UTI Healthcare Fund Direct Growth is ₹312.31 as on 21-Nov-2024.
Existing (Absolute + CAGR) as on 21-Nov-2024.
UTI Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -2.18% | -2.18% |
6 Month Returns | 23.41% | 23.41% |
1 Year Returns | 44.42% | 44.42% |
3 Years Returns | 77.37% | 21.05% |
5 Years Returns | 249.7% | 28.45% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.28% as on October 2024
₹1187 Cr as on October 2024
Sun Pharmaceuticals Industries Ltd(11.29%), Cipla Ltd(5.89%), Ajanta Pharma Ltd(5.38%), Dr Reddy's Laboratories Ltd(4.67%), Gland Pharma Ltd(3.7%) as on October 2024
Health(95.93%), Basic Materials(1.5%), Financial Services(1.04%) as on October 2024
The alpha ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
UTI Healthcare Fund Direct Growth | -1.17 | 0.84 | 2.42 |
As on October 2024
The alpha for UTI Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
UTI Healthcare Fund Direct Growth | 1.01 | 0.96 | 0.94 |
As on October 2024
The Beta for UTI Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
UTI Healthcare Fund Direct Growth | 2.87 | 0.97 | 1.21 |
As on October 2024
The sharpe ratio for UTI Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
UTI Healthcare Fund Direct Growth | 14.84 | 15.69 | 18.7 |
As on October 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.85 as on October 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.12 as on October 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
The Exit load of UTI Healthcare Fund Direct Growth is 1%